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Introduction
Genetic variants, mutations and inheritance models
The inheritance of various traits or diseases from parent to 
offspring occurs primarily through DNA. When comparing 
two random human individuals, their DNA is approximately 
99.9 % identical. The remaining 0.1 % of DNA is respon-
sible for their differences (variations) [1]. The DNA of an 
individual can change or become mutated in several ways, 
ranging from small-scale variants that affect just one or a 
few nucleotides (small substitutions, insertions and dele-
tions) [2] to large-scale alterations affecting the chromo-
some structure, for example with copy number variations or 
translocations [3].
In the case of a nucleotide change, the term ‘variant’ often 
refers to a mere difference compared with a reference genome 
(which is publically accessible online). The term ‘mutation’ 
is more used for changes which cause impairment of protein 
function and lead to disease [4]. Mutations exist in various 
types, each with differing likelihood to be damaging. Types 
that generally produce large effects are for example stop-
gain (also called nonsense), essential splice site and frame-
shift mutations, which usually cause early stops, thereby 
impairing protein formation, leading to an incomplete or 
excessively large protein. Though not necessarily damaging, 
these types of mutations understandably have the potential 
to severely impair biological function. Other so-called mis-
sense mutations more subtly change one amino acid (which 
are the building blocks of proteins), while leaving the rest 
of the protein intact. Hence, these mutations are less likely 
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to be severely damaging. Constitutions of nucleotides at a 
certain place in a gene are called alleles: for example at a 
certain place in a chromosome, one individual has allele A 
and the other individual has allele T. Since, in humans, two 
copies exist of every chromosome, individuals can be homo-
zygous for an allele (existing on both chromosomes, e.g. AA, 
CC, GG, TT) or heterozygous (existing on one chromosome, 
e.g. AC, AG, AT, CG, CT, GT). Individuals carrying only 
one copy of an allele or chromosome are hemizygous (for 
example the X-chromosome in males).
The first basic genetic inheritance models date back from 
the nineteenth century, when Gregor Mendel, an Augustin-
ian monk, posed rules for dominant and recessive inheri-
tance. These rules still constitute the basis of current views 
on certain inheritance models of human diseases, [5] which 
are nowadays referred to as ‘Mendelian’ models. Another 
present-day example reflecting Mendel’s merits is the 
Online Mendelian Inheritance in Man website (OMIM, via 
http://www.omim.org), which is a widely used online cata-
logue of human genes and genetic disorders [6]. Clinical 
examples in this article will be provided with a so-called 
MIM number, which can be used to access more related 
information on the OMIM website.
Mendel’s theory on inheritance mainly comprised two 
models: dominant and recessive. In an autosomal dominant 
inheritance pattern, a certain phenotype is caused in a hetero-
zygous individual by a single, dominantly acting allele. This 
allele can be transferred to the offspring with a 50 % chance 
for both females and males (e.g. MYH7 mutations in dilated 
cardiomyopathy, MIM#613426) [7]. In autosomal recessive 
diseases, two alleles have to be mutated for (full) manifesta-
tion of the phenotype. This can be either at the same position 
in a gene in homozygous individuals (often caused by related, 
consanguineous parents) [8] or at two different positions in a 
gene, in so-called compound heterozygous individuals (with 
one allele maternally, the other allele paternally inherited) 
[9]. In recessive disease, heterozygous carriers are usually 
healthy or only mildly affected. Sex-linked diseases follow 
different rules than autosomal diseases. Since males receive 
only one maternal X-chromosome (and therefore are hemi-
zygous) they are more likely to be affected by a mutation on 
the X-chromosome. Females have two X-chromosome cop-
ies, so mutations in one chromosome can be (partially) com-
pensated by the healthy allele on the other X-chromosome 
[10]. Y-linked diseases naturally appear only in males [11].
Clinical genetics
General introduction
Clinical genetics comprises the diagnostic process of, and 
adaptation to the medical, psychological and familial impli-
cations of genetic disease [12]. Various medical specialists 
refer a paediatric or adult patient (proband/index) with a 
suspected genetic disease to outpatient genetics clinics for 
evaluation. Medical history (including prenatal, neonatal 
period) of motor and intellectual development, physical 
examination for growth parameters, dysmorphic features 
(unusual morphology of the face and body) and pedigree 
construction (diagram representing how a trait or disease 
is segregating in a family) are important factors to assess 
the possibility for a genetic cause of the disease. Diagnostic 
differentials are established by appraising clinical informa-
tion and consulting online databases. These contain medi-
cal photos and extensive phenotypic information to provide 
assistance in pinpointing the right diagnosis in the ‘jungle’ 
of rare genetic diseases (e.g. OMIM, London Medical Data-
base—LMD) [6].
After examination, genetic diagnostic tests can be per-
formed. Examples of genetic tests are DNA sequencing 
(reading parts of DNA) of candidate genes (e.g. MYBPC3 
in dilated cardiomyopathy, MIM#615396) [12], karyotyp-
ing and array analysis (e.g. for investigating chromosomal 
abnormalities, such as Down syndrome or 22q11 deletion 
syndrome) [13]. If family members of the index patient are 
concerned about the risk of developing the same disease 
themselves or in a second child, genetic counselling with 
risk assessment, presymptomatic testing, prenatal diagnos-
tics or sometimes even preimplantation genetic screening 
(genetic profiling of embryos) can be offered [14]. Clinical 
geneticists often collaborate with research groups when they 
are unable to identify the underlying genetic defect of the 
patient’s disease. This mainly involves additional sequenc-
ing of unexplored regions of the patient’s DNA [15].
Clinical applicability in dilated cardiomyopathy
Genetic counselling can be relevant for dilated cardiomy-
opathy (DCM) patients, since the disease has been demon-
strated to frequently have a genetic origin, even in seemingly 
sporadic cases—that is, DCM patients with no self-reported 
family history of cardiomyopathy. In 1992, Michels et al. 
showed by screening family members of DCM patients with 
echocardiography that DCM is heritable in at least one in 
five patients. The majority of family members were asymp-
tomatic with only a dilated left ventricle, and some devel-
oped symptoms in the following years. Since DCM can have 
such presymptomatic stages whereby index patients appear 
to be sporadic, routine family screening with echocardiog-
raphy of family members of DCM patients is recommended 
(Fig. 1) [16]. In the case of familial DCM, genetic testing 
can subsequently be considered, particularly with accom-
panying conduction disorder(s) and/or arrhythmia [17]. 
The beneficial role of genetic diagnostics in truly sporadic 
idiopathic DCM has not been empirically substantiated yet. 
358
1 3
Neth Heart J (2015) 23:356–362
Of note, mutations in these two genes can also manifest 
themselves clinically. A deletion of arginine 14 in the PLN 
gene can, for example, cause dilated cardiomyopathy with 
attenuated electrocardiographic (ECG) R amplitudes or 
low voltages in multiple leads on the ECG [24, 25]. LMNA 
mutations in turn, typically show a low amplitude P wave 
and prolongation of the PR interval with a narrow QRS 
complex on the ECG. Furthermore, patients with these gene 
mutations are at higher risk to develop conduction disorders 
and/or arrhythmias [26].
Technological advancements
In the last decade, DNA sequencing in genetic diagnostics 
has undergone some tremendous changes. Due to technolog-
ical advancements with next-generation sequencing (NGS), 
the capacity and cost efficiency of DNA sequencing has 
grown enormously by creating the ability to screen multiple 
genes simultaneously [27]. Before NGS, Sanger sequencing 
was the standard method in clinical laboratories to screen 
for mutations. Though very reliable, this method has smaller 
throughput, meaning that usually one gene was screened at a 
time, and that the maximum number of genes to be screened 
was also practically limited. Since many genes are involved 
in the pathogenesis of cardiomyopathies (DCM for example 
has more than 45 implicated genes), NGS subsequently pro-
vides an enormous potential for improvement in terms of 
efficiency in cardiovascular genetic testing, when compared 
with Sanger sequencing [28].
The discovery rate in cardiovascular genetics has cor-
respondingly grown rapidly. In 2012, for example, using 
NGS, Herman et al. discovered the important role of the titin 
(TTN) gene in the disease aetiology of dilated cardiomyop-
athy [29]. After its successful debut in research, NGS has 
been implemented over the last years in multiple diagnostic 
centres. Here, multiple genes can be screened simultane-
In general, cardiac genetic disorders are characterised by a 
heterogeneous background, with variable penetrance and 
expressivity. This means that clinical phenotypes can vary 
within families, even when pedigrees share the same muta-
tion. Hence, one can find mutation carriers having no clini-
cal manifestations of the disease to having severe disease 
with various manifestations [18].
The diagnosis of genetic cardiomyopathies can be ben-
eficial at multiple clinical levels. In diagnostics and therapy, 
presymptomatic investigation (mainly for family members) 
could lead to possible health benefit by early treatment of dis-
ease. The potential of early treatment for mutation carriers is 
currently being assessed by the PRECARDIA trial. Here, an 
angiotensin-converting enzyme inhibitor (ACE inhibitor) is 
administered to family members of DCM patients that carry 
a (presumed) pathogenic mutation, to see if this can delay or 
prevent the occurrence of DCM [19]. In 2006, Meune et al. 
performed implantable cardiac defibrillator (ICD) implanta-
tion in patients with a lamin A/C (LMNA) mutation, who 
were only in need of a pacemaker. They showed effective-
ness in treating possibly lethal tachyarrhythmias in 42 % of 
the patients, with an appropriate shock percentage of 89 %. 
Of note, improvement of survival could not be assessed, 
since the study did not contain a control group [20]. Another 
example of therapeutic consequences is lifestyle recom-
mendations for patients with hypertrophic cardiomyopathy, 
such as abstinence from top sports [21]. Also patients with 
arrhythmogenic right ventricular dysplasia/cardiomyopathy 
are advised against practising competitive and endurance 
sports, for arrhythmia prevention [22].
In prognostics, Van Spaendonck-Zwarts et al. demon-
strated that the prevalence of mortality, heart transplantation 
and malignant ventricular arrhythmias was higher among 
DCM patients with a mutation in the phospholamban (PLN) 
or LMNA gene, compared with DCM patients who did not 
carry a mutation in diagnostically screened genes [23]. 
Fig. 1 Examples of inheritance 
in pedigrees with seemingly 
sporadic cases: a de novo, b/c 
autosomal dominant with reduced 
penetrance (= a mutation does 
not consequently cause dis-
ease), d: autosomal recessive, 
e: compound heterozygous (two 
mutations in one gene, yet in 
two different alleles, collectively 
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Besides the obvious optimisation of data quality to ensure 
actual presence of a variant, the likelihood of variants to be 
pathogenic is assessed in various ways (Fig. 2). First, one 
can assess the frequency of a certain variant in the general 
population in order to distinguish rare from common vari-
ants, by comparison with online reference genomes. The 
underlying idea here is that common variants cannot be 
causal for rare diseases [34].
Second is mutation effect assessment. Here only vari-
ants that potentially impair protein structure and/or func-
tion are selected (these mutation types are explained above, 
under ‘introduction’). Third, the likelihood of missense and 
splice-site variants to be damaging is assessed with soft-
ware programmes (SIFT and PolyPhen) that predict possi-
ble impact on the structure and function of a human protein 
using straightforward physical and comparative consider-
ations [35].
Fourth, after this initial workup of identified variants, an 
important analysis step is family segregation, which is con-
sidered the cornerstone of genetic counselling. It basically 
comprises genetic screening of affected family members, to 
see if a mutation segregates with disease. The stronger a 
mutation segregates with disease, the more likely it is to be 
causal. Fifth is functional follow-up, where mutations are 
investigated, in for example animal models, to assess their 
biological effect. Due to time and cost constraints, func-
ously in multiple patients on a single chip (so-called gene 
panel). Currently, 45 genes are being sequenced in multiple 
centres across the Netherlands. These genes are implicated 
in highly diverse biological structures and pathways, among 
which sarcomere integrity, ion channels, metabolism, 
calcium regulation and transcriptional control [30–32]. 
Alongside its application in diagnostics, NGS is sometimes 
deployed in research settings to screen for mutations in any 
desired combination of genes, or even all genes simultane-
ously. The latter is called whole exome sequencing and is 
mainly suitable for cases with large families available for 
genetic screening, or for patients in which de novo (arose in 
the genome after fertilisation) mutations are expected based 
on the pedigree. In that case, trio analysis is performed, in 
which the whole exome sequence of a patient is compared 
with that of the (healthy) parents.
With NGS, earlier shortcomings of Sanger sequencing 
in terms of throughput and cost efficiency have certainly 
been overcome. Now the genetic community is facing a 
whole new challenge though, which is adequately interpret-
ing the significance of identified variants. Genetic variants 
are frequent, and most are known to be harmless. The more 
genes are investigated, the more variants one will find. With 
the capacity of NGS to harvest so many variants, effective 
means to differentiate between innocent and pathogenic 
variants are essential [33].
Fig. 2 Global overview of 
genetic data analysis, by filtering 
for multiple criteria: (i) rare vari-
ants (by comparison with online 
reference genomes such as the 
Single Nucleotide Polymorphism 
DataBase (dbSNP), or Exome 
Sequencing Project (ESP)), (ii) 
mutation effect (previously ex-
plained) (iii) functional prediction 
(SIFT Sorting Intolerant From 
Tolerant), the likelihood of vari-
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genesis of DCM. This was recently shown by, for example, 
Roncarati et al. [36], who discovered in an extended fam-
ily with DCM the causal role of a LMNA mutation, with a 
disease-aggravating mutation in TTN. Another development 
in diagnostics is preimplantation genetic diagnostics, a tech-
nique which allows for genetic testing of an embryo, before 
its implant (e.g. in-vitro fertilisation or intracytoplasmatic 
sperm injection) [37].
For therapy, numerous efforts are being undertaken in 
the field of genetics to treat or prevent cardiac disease. In 
pharmacogenetics, genetic profiling is used as a determi-
nant for genotype-guided personalised medicine.[38] In the 
RAPID GENE trial (ReAssessment of Anti-Platelet Ther-
apy Using an InDividualized Strategy Based on GENetic 
Evaluation), point-of-care genetic testing was used to iden-
tify CYP2C19*2 carriers, which is an allele associated with 
increased rates of major adverse events. After randomisa-
tion, genetic testing proved to be an effective deciding fac-
tor to reduce high on-treatment platelet reactivity which, in 
turn, is associated with a lower complication rate [39].
Another promising treatment option is gene therapy. 
Currently, SERCA2a gene therapy trials are ongoing to 
treat patients with heart failure. Several studies have dem-
onstrated a decrease of sarco-endoplasmic reticulum cal-
cium-ATPase 2a (SERCA2a) expression and function in 
heart failure patients. In phase II of the Calcium upregu-
lation by percutaneous administration of gene therapy in 
cardiac disease (CUPID) trial, an adeno-associated virus is 
used to deliver SERCA2a to the cardiomyocytes. After 12 
months, patients with high dose showed a decrease in heart 
failure symptoms, increased functional status and reversal 
of the negative left ventricle remodelling [40]. In another 
trial involving SERCA2a gene expression modification in 
a mouse model, Wahlquist et al. [41] described how they 
improved survival for heart failure in a mouse model by 
injecting an antagonist for micro-RNA 25. Potentially in 
2015, the first gene therapy approved for clinical use will 
be rolled out (Glybera®, for treatment of lipoprotein lipase 
deficiency) [42]. Further, research will ultimately tell to 
what extent gene therapies are suitable as a treatment for 
heart failure or DCM, and if cardiogenetics will live up to its 
potential promise in the context of personalised medicine.
Concluding remarks
In the last decade, cardiovascular genetics has undergone 
tremendous progression, mainly thanks to the implementa-
tion of NGS. Hence, the pathophysiological insight into, 
among other diseases, dilated cardiomyopathy is increasing 
and modernised genetic testing has quickly been integrated 
in clinical practice. The main challenges currently reside 
on the area of improving variant interpretation and possi-
tional tests are unfortunately not available for diagnostics, 
and therefore are only occasionally deployed in genetic 
research.
The analysis methods described above can reduce the 
number of suspicious variants to a great extent. Nonetheless 
we are often left with a high number of so-called variants of 
uncertain significance (VUS), impeding effective diagnos-
tics. Hence, for patients with idiopathic dilated cardiomy-
opathy, the advent of NGS has cleared up the genetic cause 
for some patients, while generating tremendous uncertainty 
for many patients with its high number of VUSses. This 
means that, in the anticipation of genetic screening, one 
must consider carefully how many genes are to be screened. 
The principle applies that when fewer genes are screened 
(with a so-called ‘targeted approach’), less variants will 
likely be detected, thus facilitating their interpretation—at 
the same time though, sensitivity diminishes, meaning that 
finding no variant in a subset of genes does not exclude a 
genetic cause. Inversely, simply choosing a broad approach 
with whole exome sequencing will often result in an unsolv-
able wealth of variants, with a low specificity. The uncertain 
role of variants and their pathogenicity is even shown to 
extend to variants previously deemed to be causal for DCM. 
In 2013, Andreasen et al. showed, by using online mutation 
databases and large publicly available reference genome 
datasets, that ‘known DCM-causing variants’ were in fact 
more prevalent than estimates of DCM prevalence. This 
justly questioned the pathogenicity of these variants and 
even raised the question whether the prevalence of DCM is 
higher than previously estimated [34]. This was later shown 
to be likely by Hershberger et al. [32] using various estima-
tion methods.
Future perspectives
Regarding current developments in the field of cardiovas-
cular genetics, several issues will likely be addressed more 
adequately in the foreseeable future, of which a selection 
will be highlighted here.
In diagnostics, an obvious issue that needs to be 
addressed is the high number of VUSses. An important 
strategy to tackle this is data sharing. By sharing variants 
with their associated phenotypes on publicly accessible 
databases (e.g. GENCOR, via http://www.durrercenter.nl/
catalogue), the mass of cardiogenetic evidence will be more 
accessible. This will allow an efficient gain of knowledge 
and better interpretation of variants in the future. Another 
important development in disputing the numerous VUSses 
is enhanced data interpretation with multi-variant analysis. 
Here, distinction is made between disease causing variants 
and so-called effect modifiers, which enables a more ade-
quate, nuanced interpretation of the role of variants in patho-
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bly, the application of gene (regulation) therapy to treat and 
prevent dilated cardiomyopathy and other cardiovascular 
disorders. With its boosted discovery rate and increasingly 
prominent clinical role, this quickly emerging field of medi-
cine is expected to continue to have great impact on cardio-
vascular healthcare.
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